ArticleMedicine2026
Drug-induced urinary incontinence in pediatric patients: A disproportionality analysis of the FDA Adverse Event Reporting System.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.Pharmacological reports : PR · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the substantial impact of urinary incontinence (UI) on the physical and mental health of children, research on drug-induced pediatric UI (PUI) remains limited. This study aimed to identify drugs associated with PUI by analyzing data from the FDA Adverse Event Reporting System (FAERS). We analyzed FAERS data from Q1 2004 to Q4 2024 to identify PUI cases in children aged 5 to 17 years. Disproportionality signals were assessed using reporting odds ratios (RORs) and proportional reporting ratios (PRRs). Additionally, we conducted a subgroup analysis of enuresis and compared the risks of drug-induced UI between children and adults. Our analysis identified 1252 reports of PUI from the FAERS database. Montelukast was the most frequently reported drug (91 cases), followed by risperidone (74 cases). Forty drugs were significantly associated with PUI, with drugs acting on the nervous system accounting for 52.5%. The top 3 drugs with the strongest signals were glipizide (ROR = 141.1, 95% CI 37.4-532.4; PRR = 102.9), ropinirole (ROR = 125.7, 95% CI 49.8-317.2; PRR = 94.5), and sodium oxybate (ROR = 19.8, 95% CI 15.1-26.0; PRR = 18.9). Twenty-two drugs, such as montelukast, sodium oxybate, and sertraline, had a higher risk of UI in children than in adults. We also discovered unexpected associations, such as miglustat, tisagenlecleucel, and vamorolone. This study systematically identified a range of drugs, including several unexpected ones, associated with PUI. These findings enhance the understanding of the safety profile of drugs associated with PUI and provide important insights for optimizing clinical practice in pediatrics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.